LTI
DFTX

Laffer Tengler Investments’s Definium Therapeutics DFTX Stock Holding History

Laffer Tengler Investments’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6
Closed -$21 – 452
2022
Q3 		$21 Sell
6
-1
-14% -$10 ﹤0.01% 429
2022
Q2 		$64 Hold
7
– – ﹤0.01% 385
2022
Q1 		$111 Hold
7
– – ﹤0.01% 414
2021
Q4 		$138 Hold
7
– – ﹤0.01% 380
2021
Q3 		$233 Buy
+7
New +$303 ﹤0.01% 479

Other funds holding DFTX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Laffer Tengler Investments's DFTX Position: Q4 2022 in Review

Laffer Tengler Investments sold out of Definium Therapeutics (DFTX) in Q4 2022, closing a stake of 6 shares — an estimated $21 sold.

Laffer Tengler Investments first reported a position in DFTX in Q3 2021 and held it in 5 quarters. The position peaked at $233 in Q3 2021. 104 funds tracked by Wall St. Rank hold DFTX as of Q4 2022.

  • Laffer Tengler Investments reported no remaining Definium Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Laffer Tengler Investments sold 6 Definium Therapeutics shares in Q4 2022, an estimated $21.
  • Laffer Tengler Investments first reported a position in Definium Therapeutics in Q3 2021 and held it in 5 quarters.
  • Laffer Tengler Investments's Definium Therapeutics position peaked at $233 in Q3 2021.
  • 104 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2022.

Based on Laffer Tengler Investments's 13F filing for Q4 2022, filed 10 Feb 2023.